EU Pharma Reform Navigator

What the EU pharmaceutical package, the Critical Medicines Act and the HTA Regulation mean for your company.

Protection calculator

How long will your product be protected?

Estimate data protection, market protection and orphan market exclusivity under the new and the old rules, and see which regime applies to your application.

Your product

Medicine type

Example dates. Replace them with your own.

Extensions

Assumed publication in the Official Journal

15 December 2026

Drag the handle, or use the arrow keys, to try another date. Watch the “new rules apply” line move past your application date.

  • Publication 15 December 2026
  • Entry into force 4 January 2027
  • New rules apply 4 January 2029
  • Your application 1 March 2029

Result

Earliest generic or biosimilar launch

1 March 2039

9 years of data and market protection under the new rules. The old rules would give 10 years, 1 year more.

New rules apply. Your application (1 March 2029) is on or after 4 January 2029, the date the new rules apply if the Pharma Package is published on the assumed date. Applications submitted before that date keep the old protection periods. Directive Art 221(5); Regulation Art 186(5) and (10).

New and old rules compared

New rulesApplies to you

Old rules

  • Data protection
  • Voucher
  • Market protection
  • Extensions
  • Orphan exclusivity
  • Year 6: conditional generic filing

Key dates under the rules that apply

Data protection ends
1 March 2038
Market protection ends
1 March 2039
Earliest generic or biosimilar launch
1 March 2039
Generic applications assessable (only after a failed supply request)
From 1 March 2036

Regulatory protection only: patents and supplementary protection certificates are separate. New rules follow the Council texts (Directive Arts 83 to 85, 221; Regulation Arts 41 to 44, 72 to 74, 186). Old-rule periods are from our brief and still need a source. Orientation only, not legal advice.